• Home
  • Anamorelin 50mg
  • Anamorelin 50mg

Anamorelin 50mg

52134

Anamorelin is used in some countries for cancer-related anorexia and cachexia, where a person with cancer loses appetite, weight, and muscle despite trying to eat.

It has mainly been studied and used for weight loss and poor appetite in people with advanced non-small cell lung cancer or other cancers, depending on local approval.

Usual dose range: where approved, the usual adult dose is commonly 100mg once daily before food; local approval and product information should be checked because availability differs by country.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.